O. Eton

发表

Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array

V. Prieto, S. Shen, Peter S. Zhang, 2003, Journal of cutaneous pathology.

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

Suzanne F. Jones, M. Mehren, H. Burris, 2011, Cancer Chemotherapy and Pharmacology.

Phase I trial of subcutaneous recombinant human interleukin‐2 in patients with metastatic melanoma

A. Buzaid, R. Benjamin, M. Rosenblum, 2002, Cancer.

Interleukin-1 production in tumor cells of human melanoma surgical specimens.

N. Ordóñez, M. Frederick, O. Eton, 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.

A. Buzaid, S. Legha, A. Bedikian, 1999, Oncology reports.

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment

P. Hwu, G. Lizée, Kevin B. Kim, 2008, Melanoma research.

Chemotherapy, cytokines, and biochemotherapy for melanoma.

O. Eton, 2005, Cancer chemotherapy and biological response modifiers.

A phase III randomized trial of adjuvant biochemotherapy (BC) versus interferon-α-2b (IFN) in patients (pts) with high risk for melanoma recurrence.

A. Roe, R. Gonzalez, S. Legha, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, GleevecTM)

Kevin B. Kim, D. Ivan, A. H. Diwan, 2006, Journal of cutaneous pathology.

Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM)

M. Frazier, A. H. Diwan, V. Prieto, 2004 .

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study)

J. Wolchok, A. Shoushtari, M. Callahan, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports

Stephanie L. Lee, O. Eton, Anita Pudusseri, 2017, Thyroid : official journal of the American Thyroid Association.

Increase in the ability of human cancer cells to induce cytotoxic T lymphocytes by ultraviolet irradiation

M. Ross, O. Eton, K. Itoh, 1993, Cancer Immunology, Immunotherapy.

T-Lymphocyte Response in Renal Cell Carcinoma

O. Eton, M. Nakao, K. Itoh, 1995 .

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.

T. Choueiri, M. Galsky, N. Nock, 2022, JAMA oncology.

Phase II study of 'hybrid' biochemotherapy for advanced melanoma.

P. Hwu, L. Camacho, A. Bedikian, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of recombinant human interleukin‐2 and interferon‐alpha‐2a: Implications for the treatment of patients with metastatic melanoma

R. Benjamin, M. Talpaz, O. Eton, 1996, Cancer.

Evaluation of interleukin‐2 administered by continuous infusion in patients with metastatic melanoma

S. Legha, O. Eton, C. Plager, 1996, Cancer.

Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer

L. Garrison, O. Eton, P. Yu, 2019, Journal of Immunotherapy for Cancer.

Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.

M. Ross, J. Murray, A. Buzaid, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

M. Ross, C. Balch, A. Buzaid, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

Q. Dong, C. Balch, A. Buzaid, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II evaluation of bryostatin-1 in metastatic melanoma

M. Ross, A. Bedikian, O. Eton, 2001, Melanoma research.

Pilot study of high‐dose, concurrent biochemotherapy for advanced melanoma

Kevin B. Kim, A. Bedikian, O. Eton, 2004, Cancer.

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

Arijit Chakravarty, Hua Liu, Jeffrey Ecsedy, 2010, Molecular Cancer Therapeutics.

Melanoma brain metastasis: overview of current management and emerging targeted therapies

E. Kasper, E. Wong, E. Uhlmann, 2012, Expert review of neurotherapeutics.

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

J. Lee, J. Lee, A. Buzaid, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

A. Buzaid, S. Legha, A. Bedikian, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Establishment and characterization of two human myeloma cell lines secreting kappa light chains.

D. Scheinberg, A. Houghton, O. Eton, 1989, Leukemia.

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

Jeffrey E. Lee, M. Ross, A. Bedikian, 2010, Journal of Translational Medicine.

Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma

Theresa Smith, A. Bedikian, O. Eton, 2004, Melanoma research.

Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.

A. Buzaid, S. Legha, A. Bedikian, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma

M. Atkins, J. Sosman, V. Prieto, 2006, Cancer.

Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.

D. V. Von Hoff, A. Buzaid, L. Smetzer, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma.

A. Buzaid, S. Legha, A. Bedikian, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.

S. Legha, A. Bedikian, O. Eton, 1997, The cancer journal from Scientific American.

Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma.

A. Buzaid, S. Legha, A. Bedikian, 1999, Anti-cancer drugs.

Pilot study of intra-arterial cisplatin and intravenous vinblastine and dacarbazine in patients with melanoma in-transit metastases.

A. Buzaid, R. Benjamin, S. Legha, 1999, Melanoma research.

Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.

M. Ross, C. Balch, A. Buzaid, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II evaluation of temozolomide in metastatic choroidal melanoma

A. Bedikian, O. Eton, N. Papadopoulos, 2003, Melanoma research.

Phase II trial of imatinib mesylate in patients with metastatic melanoma

M. Ross, C. Ng, J. Gershenwald, 2008, British Journal of Cancer.

Biochemotherapy in patients with metastatic anorectal mucosal melanoma

Jeffrey E. Lee, L. Broemeling, M. Ross, 2004, Cancer.

Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy

J. Lee, A. Buzaid, F. Ali-Osman, 1998, Melanoma research.

Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen.

M. Ross, J. Murray, A. Buzaid, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.

J. Lee, A. Buzaid, O. Eton, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.

A. Heimberger, M. Bar‐eli, A. Onn, 2004, The Journal of investigative dermatology.

Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM).

M. Frazier, A. H. Diwan, V. Prieto, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma

A. Bedikian, O. Eton, N. Papadopoulos, 2002, Anti-cancer drugs.

A randomized phase III trial of biochemotherapy versus interferon-&agr;-2b for adjuvant therapy in patients at high risk for melanoma recurrence

M. Ross, P. Hwu, J. Gershenwald, 2009, Melanoma research.

A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer

Hua Liu, Balazs Halmos, Thomas J Lynch, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Hypercalcemia due to Parathyroid Hormone-Related Protein Secretion by Melanoma

S. Yeung, L. Deftos, O. Eton, 1998, Hormone Research in Paediatrics.

Phase II trial of N-methylformamide in patients with metastatic melanoma

D. Bajorin, A. Houghton, E. Casper, 1991, Investigational New Drugs.

Safety, Tolerability, and Pharmacology of Bortezomib in Cancer Patients with Renal Failure Requiring Dialysis: Results from a Prospective Phase 1 Study.

C. Takimoto, S. Remick, M. Karol, 2007 .

ANTI-EGFR ANTIBODY ADDED TO ONGOING ANTI-PD-1 ANTIBODY TREATMENT FOR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE FACE: TWO CASE REPORTS

Philip S. Yu, R. Cartun, O. Eton, 2020 .

Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local‐regional metastases

A. Buzaid, S. Legha, A. Bedikian, 1998, Melanoma research.

Randomized phase II study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (NSCLC)

T. Lynch, B. Halmos, O. Eton, 2007 .